Zentalis Pharmaceuticals Llc Stock Alpha and Beta Analysis
| ZNTL Stock | USD 2.12 0.11 4.93% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Zentalis Pharmaceuticals Llc. It also helps investors analyze the systematic and unsystematic risks associated with investing in Zentalis Pharmaceuticals over a specified time horizon. Remember, high Zentalis Pharmaceuticals' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Zentalis Pharmaceuticals' market risk premium analysis include:
Beta 2.64 | Alpha (0.32) | Risk 7.52 | Sharpe Ratio (0.09) | Expected Return (0.64) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Zentalis |
Zentalis Pharmaceuticals Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Zentalis Pharmaceuticals market risk premium is the additional return an investor will receive from holding Zentalis Pharmaceuticals long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Zentalis Pharmaceuticals. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Zentalis Pharmaceuticals' performance over market.| α | -0.32 | β | 2.64 |
Zentalis Pharmaceuticals expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Zentalis Pharmaceuticals' Buy-and-hold return. Our buy-and-hold chart shows how Zentalis Pharmaceuticals performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Zentalis Pharmaceuticals Market Price Analysis
Market price analysis indicators help investors to evaluate how Zentalis Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Zentalis Pharmaceuticals shares will generate the highest return on investment. By understating and applying Zentalis Pharmaceuticals stock market price indicators, traders can identify Zentalis Pharmaceuticals position entry and exit signals to maximize returns.
Zentalis Pharmaceuticals Return and Market Media
The median price of Zentalis Pharmaceuticals for the period between Thu, Nov 28, 2024 and Wed, Feb 26, 2025 is 2.92 with a coefficient of variation of 20.72. The daily time series for the period is distributed with a sample standard deviation of 0.57, arithmetic mean of 2.76, and mean deviation of 0.5. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Zentalis Pharmaceuticals, Inc. Shares Sold by Fmr LLC - MarketBeat | 12/11/2024 |
2 | Zentalis stock plunges to 52-week low of 2.64 amid market challenges - Investing.com | 01/13/2025 |
3 | Zentalis stock plunges to 52-week low, hits 2.16 - MSN | 01/24/2025 |
4 | Zentalis Pharmaceuticals Announces Strategic Restructuring to Support Late-Stage Azenosertib ... | 01/28/2025 |
5 | Zentalis Pharmaceuticals Shares Updated Clinical Data Demonstrating Meaningful Azenosertib Activity in Cyclin E1, Platinum-Resistant Ovarian Cancer | 01/29/2025 |
6 | Vanguard Group Inc. Reduces Stake in Zentalis Pharmaceuticals Inc. | 01/31/2025 |
7 | Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635 | 02/03/2025 |
8 | Acquisition by Bruns Ingmar of 16629 shares of Zentalis Pharmaceuticals subject to Rule 16b-3 | 02/05/2025 |
9 | Acquisition by Bruns Ingmar of 20000 shares of Zentalis Pharmaceuticals at 2.2828 subject to Rule 16b-3 | 02/06/2025 |
10 | Zentalis Pharmaceuticals, Inc. Given Consensus Rating of Hold by Analysts - MarketBeat | 02/11/2025 |
11 | Zentalis Pharmaceuticals Among Cheapest Stocks Insiders Are Buying Recently | 02/21/2025 |
About Zentalis Pharmaceuticals Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Zentalis or other stocks. Alpha measures the amount that position in Zentalis Pharmaceuticals has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2024 | 2025 (projected) | Days Sales Outstanding | 21.5K | 19.1K | PTB Ratio | 2.61 | 2.48 |
Zentalis Pharmaceuticals Upcoming Company Events
As portrayed in its financial statements, the presentation of Zentalis Pharmaceuticals' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Zentalis Pharmaceuticals' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Zentalis Pharmaceuticals' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Zentalis Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Zentalis Pharmaceuticals' management manipulating its earnings.
| 6th of March 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 6th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Zentalis Pharmaceuticals
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Zentalis Pharmaceuticals Backtesting, Zentalis Pharmaceuticals Valuation, Zentalis Pharmaceuticals Correlation, Zentalis Pharmaceuticals Hype Analysis, Zentalis Pharmaceuticals Volatility, Zentalis Pharmaceuticals History and analyze Zentalis Pharmaceuticals Performance. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Zentalis Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.